Literature DB >> 24757363

Suvorexant, a dual orexin receptor antagonist for the management of insomnia.

Tiffany Bennett, David Bray, Michael W Neville.   

Abstract

Suvorexant, a dual orexin receptor antagonist for the management of insomnia.

Entities:  

Year:  2014        PMID： 24757363      PMCID： PMC3989084     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  6 in total

Review 1.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

2.  First-in-class insomnia drug on the brink of approval nod.

Authors:  Randy Osborne
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

3.  Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.

Authors:  Christopher J Winrow; Anthony L Gotter; Christopher D Cox; Scott M Doran; Pamela L Tannenbaum; Michael J Breslin; Susan L Garson; Steven V Fox; Charles M Harrell; Joanne Stevens; Duane R Reiss; Donghui Cui; Paul J Coleman; John J Renger
Journal:  J Neurogenet       Date:  2011-04-08       Impact factor: 1.250

4.  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Authors:  Hong Sun; William P Kennedy; Darren Wilbraham; Nicole Lewis; Nicole Calder; Xiaodong Li; Junshui Ma; Ka Lai Yee; Susan Ermlich; Eric Mangin; Christopher Lines; Laura Rosen; Jeffrey Chodakewitz; Gail M Murphy
Journal:  Sleep       Date:  2013-02-01       Impact factor: 5.849

Review 5.  Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status.

Authors:  Michihiro Mieda; Takeshi Sakurai
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

6.  Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.

Authors:  W Joseph Herring; Ellen Snyder; Kerry Budd; Jill Hutzelmann; Duane Snavely; Kenneth Liu; Christopher Lines; Thomas Roth; David Michelson
Journal:  Neurology       Date:  2012-11-28       Impact factor: 9.910
  6 in total
  8 in total

1.  Optical probing of orexin/hypocretin receptor antagonists.

Authors:  Shi-Bin Li; Natalie Nevárez; William J Giardino; Luis de Lecea
Journal:  Sleep       Date:  2018-10-01       Impact factor: 5.849

Review 2.  Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).

Authors:  Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Joseph Keefe; Elasaf Gilbert; Jamal Hasoon; Michael E Thase; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2022-02-25

Review 3.  Insomnia in the Military: Application and Effectiveness of Cognitive and Pharmacologic Therapies.

Authors:  Vincent F Capaldi; Jessica R Kim; Antigone A Grillakis; Maura R Taylor; Carla M York
Journal:  Curr Psychiatry Rep       Date:  2015-10       Impact factor: 5.285

4.  Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.

Authors:  Takuma Matsumura; Jiro Terada; Chikara Yoshimura; Ken Koshikawa; Taku Kinoshita; Misuzu Yahaba; Kengo Nagashima; Seiichiro Sakao; Koichiro Tatsumi
Journal:  Drug Des Devel Ther       Date:  2019-02-28       Impact factor: 4.162

5.  Suvorexant improves intractable nocturnal enuresis by altering sleep architecture.

Authors:  Tohru Matsumoto
Journal:  BMJ Case Rep       Date:  2021-03-16

Review 6.  Sleep Problems in Chronic Inflammatory Diseases: Prevalence, Treatment, and New Perspectives: A Narrative Review.

Authors:  Marta Ditmer; Agata Gabryelska; Szymon Turkiewicz; Piotr Białasiewicz; Ewa Małecka-Wojciesko; Marcin Sochal
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

7.  The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys.

Authors:  Lais F Berro; Eliseu da Cruz Moreira-Junior; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

Review 8.  Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches.

Authors:  Kiran Kumar Siddappaji; Shubha Gopal
Journal:  AIMS Neurosci       Date:  2021-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.